Bluejay Diagnostics shares rise 10.05% premarket after all prefunded warrants are fully exercised, reducing outstanding shares to 972,000.

Bluejay Diagnostics (NASDAQ: BJDX) surged 10.05% in premarket trading following the announcement that all prefunded warrants from its October 2025 private placement had been fully exercised as of February 19, 2026. The company now has approximately 972,000 shares outstanding and 1.5 million cash-exercisable warrants with a $7.00+ per-share exercise price. The completion of warrant exercises likely signaled improved capital structure clarity and reduced dilution risks, bolstering investor confidence. Additionally, the firm reminded investors that recent Schedule 13G filings may not reflect its 1-for-4 reverse stock split on January 29, 2026, though this was a secondary factor. The move aligns with the stock’s sharp premarket rise, driven by the resolution of warrant-related uncertainties and the potential for increased liquidity as cash exercisable warrants remain in play.